This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 236 |
respiratory viruses | 230 |
respiratory tract | 205 |
respiratory infections | 147 |
syncytial virus | 110 |
respiratory syncytial | 109 |
respiratory virus | 92 |
lower respiratory | 78 |
tract infections | 75 |
human rhinovirus | 74 |
respiratory infection | 72 |
author funder | 70 |
granted medrxiv | 70 |
copyright holder | 69 |
respiratory illness | 66 |
version posted | 66 |
human bocavirus | 62 |
viral infections | 62 |
tract infection | 61 |
upper respiratory | 51 |
viral respiratory | 50 |
virus infections | 50 |
young children | 50 |
human metapneumovirus | 49 |
ari patients | 48 |
common cold | 48 |
influenza virus | 47 |
years old | 47 |
ari cases | 45 |
made available | 43 |
least one | 43 |
respiratory pathogens | 42 |
united states | 42 |
respiratory symptoms | 41 |
acquired pneumonia | 41 |
international license | 41 |
older adults | 40 |
case definitions | 40 |
asthma exacerbations | 40 |
respiratory viral | 39 |
systematic review | 39 |
respiratory disease | 39 |
children aged | 38 |
among children | 38 |
virus infection | 37 |
human coronavirus | 34 |
disease severity | 34 |
public health | 33 |
surveillance system | 33 |
nasal swabs | 33 |
polymerase chain | 32 |
influenza viruses | 32 |
viral infection | 32 |
chain reaction | 32 |
peer review | 32 |
statistically significant | 32 |
sore throat | 31 |
severe acute | 31 |
indigenous peoples | 30 |
cord uid | 30 |
doc id | 30 |
hospitalized children | 30 |
ari episodes | 30 |
posted april | 30 |
atopic asthma | 29 |
study period | 29 |
controlled trial | 29 |
collected swabs | 29 |
viral load | 28 |
rhinovirus infection | 28 |
epithelial cells | 28 |
emergency department | 28 |
medrxiv preprint | 27 |
otitis media | 27 |
health care | 27 |
human rhinoviruses | 27 |
cohort study | 26 |
mild ari | 26 |
dew point | 25 |
infectious diseases | 25 |
meteorological parameters | 24 |
influenza vaccination | 24 |
chest imaging | 24 |
syndromic surveillance | 24 |
hrv infection | 24 |
risk factors | 24 |
age group | 24 |
ari clusters | 23 |
seasonal influenza | 23 |
aged younger | 23 |
odds ratio | 23 |
defi ned | 23 |
supportive care | 23 |
identifi ed | 23 |
feline calicivirus | 23 |
pcr assays | 22 |
logistic regression | 22 |
reverse transcription | 22 |
age groups | 22 |
clinical features | 21 |
maternal asthma | 21 |
time pcr | 21 |
virus detection | 21 |
vp mrna | 21 |
clinical symptoms | 21 |
fi rst | 21 |
posted july | 21 |
parainfluenza virus | 21 |
human adenovirus | 20 |
viral loads | 20 |
common respiratory | 20 |
viral etiology | 20 |
ari symptoms | 20 |
prospective study | 20 |
like illness | 20 |
healthy children | 20 |
immune response | 20 |
case definition | 20 |
confidence intervals | 20 |
allele carriers | 19 |
hrv types | 19 |
frequently detected | 19 |
viral detection | 19 |
viruses detected | 18 |
rights reserved | 18 |
structured emr | 18 |
severe ari | 18 |
without permission | 18 |
host cell | 18 |
allowed without | 18 |
respiratory illnesses | 18 |
clinical characteristics | 18 |
virus detected | 18 |
asymptomatic controls | 18 |
aged years | 18 |
respiratory syndrome | 18 |
reuse allowed | 18 |
pandemic influenza | 17 |
rhinovirus infections | 17 |
acute lower | 17 |
emr parameters | 17 |
primary care | 17 |
antibiotic use | 17 |
hrv infections | 17 |
pcr assay | 17 |
acute otitis | 16 |
nha trang | 16 |
diagnostic codes | 16 |
significantly higher | 16 |
world health | 16 |
viral ari | 16 |
protective effect | 16 |
previous study | 16 |
study population | 16 |
infections among | 16 |
adjusted odds | 16 |
median age | 15 |
severe respiratory | 15 |
influenza vaccine | 15 |
positive patients | 15 |
human respiratory | 15 |
publication bias | 15 |
hospitalized patients | 15 |
first day | 15 |
early childhood | 15 |
seasonal patterns | 15 |
present study | 15 |
text analysis | 15 |
multiplex pcr | 15 |
current study | 15 |
informed consent | 15 |
study design | 14 |
race ethnicity | 14 |
infl ammatory | 14 |
influenza surveillance | 14 |
single virus | 14 |
adenovirus type | 14 |
nasopharyngeal aspirates | 14 |
cause ari | 14 |
swabs collected | 14 |
children hospitalized | 14 |
infl uenza | 14 |
influenza cases | 14 |
febrile ari | 14 |
increased risk | 14 |
sample size | 13 |
ari incidence | 13 |
aged children | 13 |
global burden | 13 |
ari case | 13 |
clinical trial | 13 |
without respiratory | 13 |
clinical severity | 13 |
actin dna | 13 |
control group | 13 |
previous studies | 13 |
hcov patients | 13 |
mean cost | 13 |
asthmatic children | 13 |
infectious disease | 13 |
posted august | 13 |
commonly detected | 13 |
general practice | 13 |
disease burden | 13 |
clinical diagnosis | 13 |
randomised controlled | 13 |
hrv type | 13 |
novel coronavirus | 13 |
induced aris | 13 |
cystic fi | 13 |
fi brosis | 13 |
severe disease | 13 |
significantly associated | 13 |
nucleic acid | 13 |
wavelet transform | 12 |
among hiv | 12 |
childhood asthma | 12 |
imaging reports | 12 |
signifi cantly | 12 |
clinical impact | 12 |
odds ratios | 12 |
bacterial pathogens | 12 |
blood pressure | 12 |
clinical data | 12 |
community cohort | 12 |
time away | 12 |
human coronaviruses | 12 |
viral pathogens | 12 |
nasal swab | 12 |
paediatric ari | 12 |
detection rates | 12 |
five years | 12 |
time series | 12 |
upper airway | 12 |
ari among | 12 |
viral co | 12 |
lwak hospital | 12 |
ari group | 12 |
clinical notes | 12 |
control study | 12 |
year old | 12 |
viral pathogen | 12 |
based surveillance | 12 |
pulmonary disease | 12 |
viral rna | 11 |
hrv species | 11 |
immune responses | 11 |
mesh terms | 11 |
among ari | 11 |
respiratory diseases | 11 |
among adults | 11 |
human parainfluenza | 11 |
among hospitalized | 11 |
days post | 11 |
severe bronchiolitis | 11 |
nonatopic asthma | 11 |
streptococcus pneumoniae | 11 |
coronavirus nl | 11 |
training base | 11 |
swab specimens | 11 |
supplementary material | 11 |
nasal secretions | 11 |
molecular methods | 11 |
developing countries | 11 |
western kenya | 11 |
staff surveillance | 11 |
hbov vp | 11 |
ari outcomes | 11 |
imaging report | 11 |
ari outcome | 11 |
host response | 11 |
body temperature | 11 |
asthma exacerbation | 11 |
text analyses | 11 |
parainfluenza viruses | 11 |
tissue culture | 11 |
viral etiologies | 11 |
birth cohort | 11 |
clinical outcomes | 10 |
ili ari | 10 |
clinical information | 10 |
rsv infection | 10 |
obstructive pulmonary | 10 |
influenza pandemic | 10 |
applied biosystems | 10 |
controlled trials | 10 |
health organization | 10 |
drug administration | 10 |
pilot study | 10 |
years hospitalized | 10 |
often detected | 10 |
penton genes | 10 |
immune system | 10 |
hospital admission | 10 |
viral aris | 10 |
detected virus | 10 |
chronic obstructive | 10 |
vp vp | 10 |
familial predisposition | 10 |
genome sequence | 10 |
nasopharyngeal swabs | 10 |
induced ari | 10 |
index case | 10 |
written informed | 10 |
reported asthma | 10 |
clinical presentation | 10 |
healthcare workers | 10 |
viral replication | 10 |
clinical trials | 10 |
hbov dna | 10 |
tested positive | 10 |
clinical case | 10 |
hrv replication | 10 |
persons years | 10 |
induced lrtis | 10 |
communityacquired pneumonia | 10 |
relative odds | 10 |
full article | 10 |
adult patients | 10 |
influenza seasons | 10 |
indirect costs | 10 |
one virus | 10 |
real time | 9 |
winter months | 9 |
search strategy | 9 |
dry mouth | 9 |
hospitalization rates | 9 |
among older | 9 |
impact diary | 9 |
birth weight | 9 |
experimental rhinovirus | 9 |
funnel plot | 9 |
children younger | 9 |
within hours | 9 |
among patients | 9 |
study using | 9 |
viral cause | 9 |
protective effects | 9 |
medical conditions | 9 |
pediatric patients | 9 |
frequent detection | 9 |
diagnostic tests | 9 |
wheezing illnesses | 9 |
possible pneumonia | 9 |
emr data | 9 |
clinical decision | 9 |
statistical analyses | 9 |
type i | 9 |
victoria lineage | 9 |
qtc interval | 9 |
collected nasal | 9 |
clinical signs | 9 |
randomized controlled | 9 |
disease control | 9 |
leading cause | 9 |
conducted using | 9 |
bocavirus infection | 9 |
confi rmed | 9 |
article screening | 9 |
requiring hospitalization | 9 |
surveillance data | 9 |
supplementary table | 9 |
electronic medical | 9 |
chest pain | 9 |
anterior nasal | 9 |
respiratory samples | 9 |
pneumonia patients | 9 |
previously described | 9 |
urine antigen | 9 |
significant difference | 9 |
children less | 9 |
carer time | 9 |
laboratory cats | 9 |
respiratory distress | 9 |
surveillance systems | 9 |
bacterial infections | 9 |
respir viruses | 9 |
rhinovirus colds | 9 |
respiratory rate | 9 |
literature review | 8 |
central vietnam | 8 |
viral pneumonia | 8 |
common among | 8 |
time reverse | 8 |
language processing | 8 |
detected viruses | 8 |
participant data | 8 |
one ari | 8 |
increased relative | 8 |
multiple viruses | 8 |
emr entries | 8 |
vaccine effectiveness | 8 |
haemophilus influenzae | 8 |
airway epithelial | 8 |
clinical disease | 8 |
early warning | 8 |
three times | 8 |
accession number | 8 |
cold virus | 8 |
time rt | 8 |
subjects compared | 8 |
hong kong | 8 |
institutional review | 8 |
common adrs | 8 |
higher risk | 8 |
times higher | 8 |
per person | 8 |
table ii | 8 |
qtc prolongation | 8 |
severe illness | 8 |
seasonal trends | 8 |
khanh hoa | 8 |
clusters amongst | 8 |
data will | 8 |
weather variables | 8 |
rna viruses | 8 |
infection among | 8 |
hrv rna | 8 |
factors associated | 8 |
classifi cation | 8 |
newly identified | 8 |
six influenza | 8 |
data collection | 8 |
may also | 8 |
winter season | 8 |
infection control | 8 |
influenza illnesses | 8 |
influenza positive | 8 |
coronavirus infections | 8 |
prospective cohort | 8 |
clinical samples | 8 |
panel viruses | 8 |
numbering system | 8 |
reverse transcriptase | 8 |
individual participant | 8 |
also found | 8 |
drd rs | 8 |
common viruses | 8 |
hospital admissions | 8 |
rabbit hemorrhagic | 8 |
year study | 8 |
data extraction | 8 |
collected specimens | 8 |
healthy volunteers | 8 |
cell cultures | 8 |
vital signs | 8 |
socioeconomic status | 8 |
population level | 8 |
infected adults | 8 |
infections due | 8 |
asthmatic adults | 8 |
copies ml | 8 |
bronchial epithelial | 8 |
genbank accession | 8 |
proinfl ammatory | 8 |
infection severity | 8 |
blood cultures | 8 |
physical examination | 8 |
performed using | 8 |
small number | 8 |
intensive care | 8 |
rural western | 8 |
whose mothers | 8 |
viral coinfection | 8 |
clinical course | 8 |
ethics committee | 8 |
atypical bacteria | 8 |
ari outbreak | 8 |
commonly associated | 8 |
among infants | 8 |
hemorrhagic disease | 8 |
human enterovirus | 7 |
gold standard | 7 |
related asthma | 7 |
high viral | 7 |
virus type | 7 |
heart rate | 7 |
runny nose | 7 |
statistical analysis | 7 |
positive samples | 7 |
well known | 7 |
ari cda | 7 |
test results | 7 |
infants whose | 7 |
infant dyads | 7 |
based study | 7 |
blood samples | 7 |
hiv status | 7 |
ari surveillance | 7 |
adhesion molecule | 7 |
cohort studies | 7 |
strongly associated | 7 |
study personnel | 7 |
transport medium | 7 |
also detected | 7 |
confidence interval | 7 |
ari episode | 7 |
regression model | 7 |
asthma symptoms | 7 |
tract illness | 7 |
human influenza | 7 |
asymptomatic children | 7 |
nucleotide sequence | 7 |
acute wheezing | 7 |
rhinovirus serotypes | 7 |
will include | 7 |
death due | 7 |
rhinovirus type | 7 |
per child | 7 |
confirmed influenza | 7 |
clinical characterization | 7 |
new respiratory | 7 |
multiplex real | 7 |
risk factor | 7 |
infl ammation | 7 |
phylogenetic analysis | 7 |
negative patients | 7 |
chn bj | 7 |
based methods | 7 |
schizophrenic patients | 7 |
decision making | 7 |
significant differences | 7 |
vietnamese children | 7 |
propensity score | 7 |
nasal self | 7 |
nucleic acids | 7 |
less likely | 7 |
laboratory data | 7 |
asthma compared | 7 |
common colds | 7 |
specific clinical | 7 |
medical record | 7 |
detection rate | 7 |
care unit | 7 |
trial vitamin | 7 |
atopic predisposition | 7 |
economic impact | 7 |
major cause | 7 |
coronavirus oc | 7 |
acute asthma | 7 |
studies will | 7 |
nasal obstruction | 7 |
natural language | 7 |
structured data | 7 |
pcr results | 7 |
child care | 7 |
data sources | 7 |
nasopharyngeal secretions | 7 |
among inpatients | 7 |
previously published | 7 |
patients aged | 7 |
diagnostic yield | 7 |
three years | 7 |
rsv infections | 7 |
hbov viral | 7 |
effect size | 7 |
pcr testing | 7 |
sentinelles network | 7 |
infected cells | 7 |
recent studies | 7 |
infection human | 7 |
trial duration | 7 |
healthy preschool | 7 |
newly discovered | 7 |
skin prick | 7 |
normal range | 7 |
detected among | 7 |
systematic literature | 7 |
nasopharyngeal samples | 7 |
ari cluster | 7 |
ili case | 7 |
pneumonia requiring | 7 |
control studies | 7 |
ari hospitalizations | 7 |
asymptomatic periods | 7 |
positive episodes | 7 |
amino acid | 7 |
participants experiencing | 7 |
children presenting | 7 |
standard deviation | 7 |
one study | 7 |
included studies | 7 |
viral nucleic | 7 |
another respiratory | 7 |
international committee | 7 |
indigenous communities | 7 |
samples positive | 7 |
older children | 7 |
hospitalized infants | 7 |
influenza season | 7 |
transcription polymerase | 7 |
multiplex rt | 7 |
early life | 7 |
meteorological parameter | 7 |
clinical manifestations | 7 |
infection prevention | 7 |
without symptoms | 7 |
studies using | 6 |
eligible studies | 6 |
dual infection | 6 |
human airway | 6 |
virus positive | 6 |
health services | 6 |
cell culture | 6 |
childhood ari | 6 |
square test | 6 |
adverse events | 6 |
outpatient visit | 6 |
prick test | 6 |
laboratory tests | 6 |
innate immune | 6 |
influenza infection | 6 |
hbov loads | 6 |
pcr products | 6 |
relatively low | 6 |
throat swabs | 6 |
mutant allele | 6 |
whole blood | 6 |
infants hospitalized | 6 |
reactive protein | 6 |
familial atopic | 6 |
significant protective | 6 |
infected patients | 6 |
proportion positive | 6 |
whole genome | 6 |
demographic information | 6 |
ari detection | 6 |
virus interference | 6 |
moderate ari | 6 |
viral aetiology | 6 |
ill child | 6 |
developed countries | 6 |
dna concentration | 6 |
simultaneous detection | 6 |
high proportion | 6 |
causal role | 6 |
infant respiratory | 6 |
kemri cdc | 6 |
asymptomatic infections | 6 |
dominant inflammation | 6 |
early detection | 6 |
ari treatment | 6 |
ser ser | 6 |
pathogens associated | 6 |
clinical specimens | 6 |
uc davis | 6 |
reported maternal | 6 |
acute bronchiolitis | 6 |
ari studies | 6 |
specimen collection | 6 |
fcv infection | 6 |
ola treatment | 6 |
may result | 6 |
children human | 6 |
general hospital | 6 |
blood culture | 6 |
least two | 6 |
two studies | 6 |
old age | 6 |
viruses associated | 6 |
detection sensitivity | 6 |
oxygen saturation | 6 |
middle ear | 6 |
see supplementary | 6 |
active viral | 6 |
incubation period | 6 |
less common | 6 |
health organisation | 6 |
review board | 6 |
infect dis | 6 |
code set | 6 |
review will | 6 |
high prevalence | 6 |
lung disease | 6 |
systematic analysis | 6 |
related hospitalizations | 6 |
relatively small | 6 |
complete genome | 6 |
daily doses | 6 |
care attendance | 6 |
picornavirus infections | 6 |
per minute | 6 |
mixed infections | 6 |
pneumococcal disease | 6 |
metapneumovirus infection | 6 |
high mortality | 6 |
respiratory bacteria | 6 |
ct value | 6 |
higher rates | 6 |
african adults | 6 |
minor group | 6 |
diagnostic testing | 6 |
clinically relevant | 6 |
molecular detection | 6 |
atypical bacterial | 6 |
will help | 6 |
predictive value | 6 |
samples collected | 6 |
subcutaneous edema | 6 |
observational study | 6 |
clinical outcome | 6 |
point estimate | 6 |
febrile respiratory | 6 |
discriminatory value | 6 |
related hospitalization | 6 |
study center | 6 |
across trials | 6 |
medical indications | 6 |
allergen sensitization | 6 |
better understanding | 6 |
mutant alleles | 6 |
two different | 6 |
many hospitals | 6 |
electronic health | 6 |
respiratory secretions | 6 |
search will | 6 |
attributable fractions | 6 |
sensitivity analysis | 6 |
lower ari | 6 |
effi cacy | 6 |
receptor binding | 6 |
associated ari | 6 |
viral testing | 6 |
dose vitamin | 6 |
ari severity | 6 |
pathogen detection | 6 |
tract disease | 6 |
molecular diagnosis | 6 |
tract specimens | 6 |
compare cda | 6 |
antibiotic therapy | 6 |
tract samples | 6 |
specific ige | 6 |
newly identifi | 6 |
viral shedding | 6 |
without asthma | 6 |
adult volunteers | 6 |
cystic fibrosis | 5 |
authors declare | 5 |
signifi cant | 5 |
overall effect | 5 |
plos one | 5 |
new zealand | 5 |
year prospective | 5 |
underlying conditions | 5 |
contact tracing | 5 |
resplex ii | 5 |
childhood pneumonia | 5 |
study team | 5 |
data elements | 5 |
ecological studies | 5 |
care alone | 5 |
positively associated | 5 |
children without | 5 |
tract illnesses | 5 |
time polymerase | 5 |
descriptive statistics | 5 |
viruses without | 5 |
primary comparison | 5 |
preferred reporting | 5 |
intercellular adhesion | 5 |
published study | 5 |
retrospective study | 5 |
sent home | 5 |
healthcare utilization | 5 |
respiratory specimens | 5 |
pharyngeal swab | 5 |
swabs taken | 5 |
invasive pneumococcal | 5 |
hrv detections | 5 |
based assays | 5 |
societal perspective | 5 |
may occur | 5 |
coding sequences | 5 |
episode onset | 5 |
bronchiolitis severity | 5 |
dna levels | 5 |
studies reporting | 5 |
oropharyngeal swabs | 5 |
mycoplasma pneumoniae | 5 |
gastrointestinal tract | 5 |
viruses using | 5 |
ray reports | 5 |
scoring systems | 5 |
pneumococcal pneumonia | 5 |
hcov infections | 5 |
pathogen identified | 5 |
australian children | 5 |
dis doi | 5 |
coding region | 5 |
patients shedding | 5 |
rapid diagnosis | 5 |
ed human | 5 |
episodes positive | 5 |
pharmacokinetic parameters | 5 |
severe clinical | 5 |
virus strain | 5 |
calendar day | 5 |
ari caused | 5 |
regression analysis | 5 |
sample adequacy | 5 |
nasal congestion | 5 |
hadv strains | 5 |
daxing district | 5 |
hbov replication | 5 |
symptom onset | 5 |
dual respiratory | 5 |
hospitalizations among | 5 |
rhinovirus rna | 5 |
based studies | 5 |
hospitalization among | 5 |
usual activity | 5 |
distress syndrome | 5 |
hospital stay | 5 |
rs mutant | 5 |
virus cases | 5 |
respiratory failure | 5 |
healthcare worker | 5 |
high hbov | 5 |
care areas | 5 |
serum antibody | 5 |
patient care | 5 |
another virus | 5 |
asthma studies | 5 |
sialic acid | 5 |
white blood | 5 |
previous days | 5 |
children respiratory | 5 |
comprehensive detection | 5 |
summary data | 5 |
rhinovirus species | 5 |
wheezing illness | 5 |
first weeks | 5 |
sequence analysis | 5 |
hcov cases | 5 |
dosing regimen | 5 |
seven hadv | 5 |
rs ser | 5 |
pcr negative | 5 |
viral culture | 5 |
considered statistically | 5 |
mean age | 5 |
nonpharmaceutical interventions | 5 |
heart disease | 5 |
disease caused | 5 |
related exacerbations | 5 |
plus supportive | 5 |
primary outcome | 5 |
community epidemiology | 5 |
atypical antipsychotics | 5 |
index visit | 5 |
specimens tested | 5 |
year period | 5 |
among young | 5 |
randomized trial | 5 |
infected cats | 5 |
th day | 5 |
patients seen | 5 |
clinical specimen | 5 |
clinical significance | 5 |
age distribution | 5 |
first year | 5 |
major group | 5 |
days duration | 5 |
patients younger | 5 |
diseases society | 5 |
controlled clinical | 5 |
significant association | 5 |
analyses will | 5 |
large number | 5 |
virus shedding | 5 |
seasonal distribution | 5 |
among outpatients | 5 |
viral detections | 5 |
attributable fraction | 5 |
symptomatic illness | 5 |
assess disease | 5 |
secondary outcomes | 5 |
reporting items | 5 |
warning system | 5 |
higher among | 5 |
high frequency | 5 |
random effects | 5 |
routinely available | 5 |
new virus | 5 |
ari hospitalization | 5 |
detection algorithms | 5 |
calicivirus infection | 5 |
weather parameters | 5 |
clinical relevance | 5 |
widely available | 5 |
white children | 5 |
night sweats | 5 |
exclusion criteria | 5 |
bordetella pertussis | 5 |
several studies | 5 |
maternal atopic | 5 |
children using | 5 |
samples using | 5 |
severity score | 5 |
acute gastroenteritis | 5 |
allowed us | 5 |
observational studies | 5 |
foster city | 5 |
difficulty breathing | 5 |
african american | 5 |
sentinel surveillance | 5 |
mg day | 5 |
reference standard | 5 |
chest radiographs | 5 |
healthy individuals | 5 |
illness among | 5 |
conjugate vaccine | 5 |
health indications | 5 |
older age | 5 |
outpatient visits | 5 |
two models | 5 |
induced wheezing | 5 |
child health | 5 |
adverse effects | 5 |
different clinical | 5 |
influenza panel | 5 |
social determinants | 5 |
severe asthma | 5 |
reviewers will | 5 |
described previously | 5 |
emerging respiratory | 5 |
see table | 5 |
vs mmhg | 5 |
pcr panel | 5 |
indigenous population | 5 |
ed visits | 5 |
ammatory immune | 5 |
chronic medical | 5 |
using data | 5 |
identifi cation | 5 |
small sample | 5 |
cutoff values | 5 |
influenza activity | 5 |
amplifi cation | 5 |
patient management | 5 |
sectional study | 5 |
molecular evolutionary | 5 |
standard error | 5 |
much less | 5 |
study human | 5 |
bacterial pneumonia | 5 |
care visit | 5 |
lung tissue | 5 |
frequent adrs | 5 |
control groups | 5 |
systematic reviews | 5 |
ari icd | 5 |
rapid detection | 5 |
factors related | 5 |
increased severity | 5 |
pediatric population | 5 |
also reported | 5 |
influenza episodes | 5 |
virus strains | 5 |
underlying disease | 5 |
geographical region | 5 |
french sentinelles | 5 |
previous work | 5 |
new molecular | 5 |
study protocol | 5 |
coronavirus hku | 5 |
one doi | 5 |
based testing | 5 |
two groups | 5 |
categorical variables | 5 |
dry season | 4 |
drug reactions | 4 |
fold increased | 4 |
wupyv reactivation | 4 |
medical intervention | 4 |
mixed viral | 4 |
costs associated | 4 |
hoa general | 4 |
infant viral | 4 |
positive predictive | 4 |
young adults | 4 |
diffi cult | 4 |
reported fever | 4 |
poverty line | 4 |
measles immunisation | 4 |
panel virus | 4 |
medical care | 4 |
burden estimates | 4 |
antigen tests | 4 |
amongst staff | 4 |
three weather | 4 |
polyomaviruses ki | 4 |
younger children | 4 |
host range | 4 |
significant role | 4 |
highly virulent | 4 |
sinus tissue | 4 |
increased appetite | 4 |
genetic variation | 4 |
surgical masks | 4 |
impact data | 4 |
stranded rna | 4 |
outpatient clinics | 4 |
neutralizing antibody | 4 |
seasonal variation | 4 |
ari cdas | 4 |
four cats | 4 |
medical research | 4 |
master mix | 4 |
patients admitted | 4 |
likelihood ratio | 4 |
severely ill | 4 |
become available | 4 |
host cells | 4 |
also identified | 4 |
three months | 4 |
comt rs | 4 |
indonesian children | 4 |
week follow | 4 |
transmission dynamics | 4 |
elderly individuals | 4 |
study child | 4 |
hela cells | 4 |
leisure time | 4 |
molecular epidemiological | 4 |
natural history | 4 |
fi nd | 4 |
hospital discharge | 4 |
childhood origins | 4 |
sample collection | 4 |
family parvoviridae | 4 |
hospital settings | 4 |
common causes | 4 |
recurrent wheezing | 4 |
spf kittens | 4 |
enrolled children | 4 |
chronic lung | 4 |
household crowding | 4 |
vast majority | 4 |
like receptors | 4 |
human adenoviruses | 4 |
logical operand | 4 |
climate change | 4 |
heparan sulfate | 4 |
significant effect | 4 |
weekly number | 4 |
ari children | 4 |
viral coinfections | 4 |
ari ili | 4 |
critically ill | 4 |
multiple viral | 4 |
institutional thesis | 4 |
van der | 4 |
infections may | 4 |
among cases | 4 |
high rate | 4 |
chronic respiratory | 4 |
bacteria codetection | 4 |
mild upper | 4 |
assess whether | 4 |
phylogenetic analyses | 4 |
bocavirus infections | 4 |
airway specimens | 4 |
health systems | 4 |
pneumococcal conjugate | 4 |
pore complex | 4 |
ari infection | 4 |
findings reinforce | 4 |
review boards | 4 |
antigenic variation | 4 |
automated text | 4 |
patients without | 4 |
respiratory pathogen | 4 |
screening will | 4 |
host immunity | 4 |
virus types | 4 |
respiratory epithelium | 4 |
health clinic | 4 |
higher poverty | 4 |
der hoek | 4 |
pediatric infectious | 4 |
record review | 4 |
social status | 4 |
acute disease | 4 |
antibiotic treatment | 4 |
ari outbreaks | 4 |
determined based | 4 |
common cause | 4 |
adjusted analyses | 4 |
calicivirus isolates | 4 |
one respiratory | 4 |
economic research | 4 |
day care | 4 |
causative agents | 4 |
infected students | 4 |
associated lower | 4 |
severe influenza | 4 |
body weight | 4 |
lower risk | 4 |
analysis revealed | 4 |
reference laboratory | 4 |
containing approximately | 4 |
adults admitted | 4 |
next day | 4 |
viruses among | 4 |
reported previously | 4 |
weeks prior | 4 |
remains unclear | 4 |
week period | 4 |
molecular characterization | 4 |
primary research | 4 |
health records | 4 |
antigen testing | 4 |
using molecular | 4 |
government report | 4 |
identify pneumonia | 4 |
catchment area | 4 |
questions will | 4 |
month period | 4 |
healthy adults | 4 |
cough remedies | 4 |
overall performance | 4 |
poorly understood | 4 |
organizing pneumonia | 4 |
wheezy bronchitis | 4 |
studies used | 4 |
upper airways | 4 |
patients attending | 4 |
significant heterogeneity | 4 |
herd immunity | 4 |
illnesses caused | 4 |
infection studies | 4 |
studies investigating | 4 |
infections will | 4 |
mild acute | 4 |
lowering effect | 4 |
term care | 4 |
preventive measures | 4 |
complete hrv | 4 |
iu vitamin | 4 |
genetic diversity | 4 |
still anorectic | 4 |
one group | 4 |
without fever | 4 |
cell count | 4 |
small amounts | 4 |
large proportion | 4 |
calculated using | 4 |
rapid antigen | 4 |
longitudinal cohort | 4 |
reduced risk | 4 |
disease among | 4 |
bacterial infection | 4 |
adult asthma | 4 |
associated hospitalizations | 4 |
culture medium | 4 |
new human | 4 |
using parent | 4 |
tract virus | 4 |
missing data | 4 |
multiplex reverse | 4 |
study included | 4 |
pleuritic chest | 4 |
following symptoms | 4 |
organ culture | 4 |
cell receptors | 4 |
prevalent among | 4 |
diagnostic test | 4 |
sensitivity analyses | 4 |
estimated due | 4 |
relevant cutoff | 4 |
based cohort | 4 |
published since | 4 |
competing interests | 4 |
symptoms may | 4 |
patients years | 4 |
adults aged | 4 |
different strains | 4 |
chi minh | 4 |
related disparities | 4 |
healthy controls | 4 |
human bocaviruses | 4 |
nl may | 4 |
hrv detection | 4 |
small bowel | 4 |
indigenous groups | 4 |
severe pneumonia | 4 |
emergency room | 4 |
studies conducted | 4 |
sensitive pcr | 4 |
substantial disease | 4 |
previous meta | 4 |
clinical practice | 4 |
efficacy outcome | 4 |
virus testing | 4 |
ser gly | 4 |
united nations | 4 |
defi ne | 4 |
pneumonia cases | 4 |
south africa | 4 |
sputum samples | 4 |
hcov seasonality | 4 |
vaccine strain | 4 |
concurrent diarrhea | 4 |
dose size | 4 |
situ hybridization | 4 |
first reported | 4 |
meteorological factor | 4 |
asymptomatic subjects | 4 |
medical records | 4 |
epidemiological week | 4 |
initial studies | 4 |
rural kenya | 4 |
enrolled patients | 4 |
coronavirus disease | 4 |
post episode | 4 |
paediatric emergency | 4 |
virus epidemiology | 4 |
viral identification | 4 |
may provide | 4 |
side effects | 4 |
social factors | 4 |
higher rate | 4 |
temperature cut | 4 |
two additional | 4 |
lower viral | 4 |
two weeks | 4 |
atypical antipsychotic | 4 |
hbov infections | 4 |
risk groups | 4 |
pneumonia among | 4 |
epidemiological profile | 4 |
disease course | 4 |
search terms | 4 |
kg body | 4 |
virus isolation | 4 |
cell surface | 4 |
laboratory confirmation | 4 |
minh city | 4 |
research ethics | 4 |
hrvs may | 4 |
peripheral blood | 4 |
days prior | 4 |
broad range | 4 |
epidemiological studies | 4 |
detecting respiratory | 4 |
patients infected | 4 |
i ifn | 4 |
phylogenetic trees | 4 |
ho chi | 4 |
study sample | 4 |
chronic bronchitis | 4 |
east asia | 4 |
illness severity | 4 |
even though | 4 |
positive specimens | 4 |
integrated management | 4 |
general practitioners | 4 |
poisson regression | 4 |
conventional pcr | 4 |
adverse drug | 4 |
care system | 4 |
gene expression | 4 |
less frequent | 4 |
study among | 4 |
maximum likelihood | 4 |
nervous system | 4 |
epidemiologically associated | 4 |
alaska natives | 4 |
trial effect | 4 |
nasal discharge | 4 |
acute infection | 4 |
human infection | 4 |
clinical illness | 4 |
reference cases | 4 |
pediatric intensive | 4 |
clinical management | 4 |
biosystems foster | 4 |
identify patients | 4 |
free text | 4 |
etiological role | 4 |
recurrent respiratory | 4 |
particularly among | 4 |
unvaccinated cats | 4 |
less severe | 4 |
viral diversity | 4 |
ari definition | 4 |
erythrocyte sedimentation | 4 |
causative role | 4 |
epidemiological data | 4 |
infections caused | 4 |
using real | 4 |
rapid viral | 4 |
pcr primers | 4 |
cold symptoms | 4 |
census tract | 4 |
nuclear pore | 4 |
aetiological role | 4 |
bacterial coinfections | 4 |
different age | 4 |
tertiary care | 4 |
south east | 4 |
parvovirus epidemiologically | 4 |
demographic data | 4 |
determine whether | 4 |
regression models | 4 |
patients hospitalized | 4 |
positive cases | 4 |
serious adverse | 4 |
surveillance study | 4 |
aripiprazole treatment | 4 |
hospital based | 4 |
genbank database | 4 |
health surveillance | 4 |
clinically significant | 4 |
rhino enterovirus | 4 |
reference ari | 4 |
supplementary materials | 4 |
inpatient locations | 4 |
african children | 4 |
help us | 4 |
identifying patients | 4 |
differ significantly | 4 |
symptom score | 4 |
ct values | 4 |
broad spectrum | 4 |
chest infection | 4 |
infect humans | 4 |
oprm rs | 4 |
interquartile range | 4 |
influenza epidemics | 4 |
novel parvovirus | 4 |
study site | 4 |
influenza hospitalizations | 4 |
mg kg | 4 |
chlamydia pneumoniae | 4 |
data collected | 4 |
dual infections | 4 |
protein vi | 4 |
epithelial cell | 4 |
detection methods | 4 |
infi ltration | 4 |
higher proportion | 4 |
chart review | 4 |
sole hrv | 4 |
bacterial detection | 4 |
interferon response | 4 |
risk staff | 4 |
old spf | 4 |
pcr test | 4 |
pandemic ari | 4 |
within days | 4 |
molecular typing | 4 |
household visits | 4 |
influenza hospitalization | 4 |
routine vaccination | 4 |
southern hemisphere | 4 |
incidence among | 4 |
additional viruses | 4 |
affected students | 3 |
infection research | 3 |
using population | 3 |
severe outcomes | 3 |
infection versus | 3 |
partly explain | 3 |
childhood wheezing | 3 |
disease surveillance | 3 |
viral group | 3 |
oral vitamin | 3 |
novel swine | 3 |
among us | 3 |
study will | 3 |
international study | 3 |
peak malaria | 3 |
type infection | 3 |
clinic visit | 3 |
index outpatient | 3 |
including human | 3 |
novel human | 3 |
available data | 3 |
adults hospitalized | 3 |
diagnostic assays | 3 |
ari may | 3 |
infections human | 3 |
closely related | 3 |
two independent | 3 |
influenzae type | 3 |
abstract screening | 3 |
asthma rhinovirus | 3 |
hrv aris | 3 |
exact test | 3 |
index visits | 3 |
multiple infections | 3 |
severe complications | 3 |
rst year | 3 |
eastern respiratory | 3 |
blood counts | 3 |
sedimentation rate | 3 |
low sample | 3 |
without clinical | 3 |
prone children | 3 |
nl infection | 3 |
antiviral agents | 3 |
final model | 3 |
cell lines | 3 |
microsoft corp | 3 |
studies presenting | 3 |
excess carer | 3 |
idexx veterinary | 3 |
adaptive immune | 3 |
detect respiratory | 3 |
influenza transmission | 3 |
heterogeneity across | 3 |
milder clinical | 3 |
time spent | 3 |
random sample | 3 |
reported increased | 3 |
antibody levels | 3 |
rate ratios | 3 |
prevention measures | 3 |
network analysis | 3 |
growing body | 3 |
one patient | 3 |
cantly higher | 3 |
blood chemistry | 3 |
black children | 3 |
disease syndrome | 3 |
adrenergic receptors | 3 |
increased ari | 3 |
afe estimates | 3 |
key outcomes | 3 |
eukaryotic initiation | 3 |
higher mortality | 3 |
clinical note | 3 |
age months | 3 |
inappropriate antibiotic | 3 |
common virus | 3 |
studies published | 3 |
capsid protein | 3 |
across studies | 3 |
exceeding words | 3 |
wu polyomavirus | 3 |
ige levels | 3 |
cohort followed | 3 |
using multiplex | 3 |
hispanic ethnicity | 3 |
ineffi cient | 3 |
causative pathogens | 3 |
benign prostatic | 3 |
protein levels | 3 |
peripancreatic fat | 3 |
clear evidence | 3 |
negative chest | 3 |
infections respiratory | 3 |
bias will | 3 |
circulate widely | 3 |
severe atypical | 3 |
sample sizes | 3 |
identify ari | 3 |
significantly lower | 3 |
single viral | 3 |
clinical studies | 3 |
origin influenza | 3 |
whereas hrv | 3 |
aris identified | 3 |
much lower | 3 |
emergency departments | 3 |
report classifier | 3 |
science citation | 3 |
refl ect | 3 |
weeks later | 3 |
viruses isolated | 3 |
otherwise healthy | 3 |
size may | 3 |
human picornavirus | 3 |
home visit | 3 |
pcr methods | 3 |
respiratory exacerbations | 3 |
severe community | 3 |
persistent infection | 3 |
tock seng | 3 |
using pcr | 3 |
hrvs cause | 3 |
clinical diagnoses | 3 |
common viral | 3 |
without concurrent | 3 |
staff syndromic | 3 |
underlying medical | 3 |
realtime pcr | 3 |
acid extraction | 3 |
infected persons | 3 |
infection outcomes | 3 |
future work | 3 |
hrv strains | 3 |
ms ms | 3 |
medical language | 3 |
antigenic sites | 3 |
symptoms associated | 3 |
valent pneumococcal | 3 |
managed aris | 3 |
cause respiratory | 3 |
future study | 3 |
pcr master | 3 |
infections occur | 3 |
among persons | 3 |
day decreased | 3 |
seasonal respiratory | 3 |
positive result | 3 |
extracted data | 3 |
defi nition | 3 |
viruses viral | 3 |
different numbers | 3 |
lipoprotein receptor | 3 |
viral genome | 3 |
poverty levels | 3 |
viruses causing | 3 |
tcid ml | 3 |
study conducted | 3 |
study presents | 3 |
epidemiologic studies | 3 |
weather covariates | 3 |
specifi cally | 3 |
studies reported | 3 |
see sect | 3 |
study confirms | 3 |
viral targets | 3 |
severe multifocal | 3 |
human polyomaviruses | 3 |
nested pcr | 3 |
ili patients | 3 |
detect ari | 3 |
interquartile ranges | 3 |
high power | 3 |
latin america | 3 |
cda components | 3 |
cost data | 3 |
diagnostic equivalence | 3 |
moderately severe | 3 |
emergent acute | 3 |
antibody titer | 3 |
month old | 3 |
including two | 3 |
antibiotic resistance | 3 |
fl uid | 3 |
inverted terminal | 3 |
many physicians | 3 |
ifn induction | 3 |
episodes per | 3 |
seasonal pattern | 3 |
lower airway | 3 |
recent study | 3 |
clinical laboratory | 3 |
cost burden | 3 |
reaction assays | 3 |
epidemic period | 3 |
significantly less | 3 |
children followed | 3 |
southern central | 3 |
ari compared | 3 |
viral upper | 3 |
hospitalized vietnamese | 3 |
severe lower | 3 |
hcov subtypes | 3 |
index encounter | 3 |
buenos aires | 3 |
month study | 3 |
possible cause | 3 |
included study | 3 |
perpetuity preprint | 3 |
high risk | 3 |
study found | 3 |
male gender | 3 |
suffi cient | 3 |
nasal epithelial | 3 |
continuous surveillance | 3 |
pcr techniques | 3 |
climate zone | 3 |
annual incidence | 3 |
seeking healthcare | 3 |
novel influenza | 3 |
study aims | 3 |
experimental animal | 3 |
antiviral groups | 3 |
case group | 3 |
dna polymerase | 3 |
week old | 3 |
patients enrolled | 3 |
strain bjdx | 3 |
medical social | 3 |
fi nding | 3 |
analysis global | 3 |
specific primers | 3 |
terminal repeat | 3 |
although hbov | 3 |
aged less | 3 |
us children | 3 |
many studies | 3 |
picornavirus infection | 3 |
healthy subjects | 3 |
community participants | 3 |
unnecessary antibiotic | 3 |
might partly | 3 |
children admitted | 3 |
results will | 3 |
households clinical | 3 |
field cats | 3 |
virus neutralizing | 3 |
point map | 3 |
complete blood | 3 |
positive airway | 3 |
accompanying symptoms | 3 |
infant hrv | 3 |
naturally acquired | 3 |
predominant viruses | 3 |
south african | 3 |
judicious use | 3 |
bacteria codetections | 3 |
mean costs | 3 |
acute exacerbations | 3 |
orthostatic hypotension | 3 |
repeated measures | 3 |
racial ethnic | 3 |
personality disorder | 3 |
baseline vitamin | 3 |
housekeeping gene | 3 |
time period | 3 |
iriis study | 3 |
hbov infection | 3 |
health policy | 3 |
require hospitalisation | 3 |
old children | 3 |
population density | 3 |
sudden cardiac | 3 |
clinical profiles | 3 |
low incidence | 3 |
veterinary medicine | 3 |
clinical evaluation | 3 |
infant infection | 3 |
frequently associated | 3 |
summer months | 3 |
atypical pneumonia | 3 |
viral acute | 3 |
viral transport | 3 |
initiation factor | 3 |
seasonal ari | 3 |
multiplex pcrs | 3 |
infections date | 3 |
actin gene | 3 |
also evident | 3 |
ari risk | 3 |
low birth | 3 |
positive associations | 3 |
cellular receptor | 3 |
genetics analysis | 3 |
pathology service | 3 |
etiologic role | 3 |
new york | 3 |
workplace policies | 3 |
mortality rate | 3 |
induced asthma | 3 |
detected per | 3 |
interval prolongation | 3 |
requires investigation | 3 |
independent variables | 3 |
ili criteria | 3 |
febrile acute | 3 |
stranded dna | 3 |
dry ice | 3 |
attributable risk | 3 |
attending physician | 3 |
experiencing one | 3 |
future asthma | 3 |
virus isolations | 3 |
tan tock | 3 |
identified among | 3 |
published literature | 3 |
pneumonia case | 3 |
gly gly | 3 |
detection among | 3 |
hand disinfection | 3 |
plasma concentrations | 3 |
high detection | 3 |
infection causes | 3 |
molecular virus | 3 |
determined using | 3 |
ssrna genome | 3 |
nationally representative | 3 |
single hrv | 3 |
low levels | 3 |
one additional | 3 |
regulatory factor | 3 |
nursing homes | 3 |
hcw ari | 3 |
specimens collected | 3 |
ill patients | 3 |
authors will | 3 |
achieved using | 3 |
sudden onset | 3 |
racial disparities | 3 |
examined whether | 3 |
mild self | 3 |
free days | 3 |
young age | 3 |
bolus doses | 3 |
severe enough | 3 |
uneventful recovery | 3 |
wheezing children | 3 |
epidemiological information | 3 |
increasing age | 3 |
form will | 3 |
toward defining | 3 |
infections viral | 3 |
rob assessment | 3 |
hadv species | 3 |
clinical utility | 3 |
contributing factor | 3 |
immunofl uorescence | 3 |
unit associated | 3 |
mortality due | 3 |
prolonged shedding | 3 |
electronic surveillance | 3 |
negex algorithm | 3 |
aged months | 3 |
lung inflammation | 3 |
using stata | 3 |
training set | 3 |
nongovernmental report | 3 |
lrti subgroup | 3 |
virulent strains | 3 |
dna viruses | 3 |
rhinoviruses reduce | 3 |
pneumonia cdas | 3 |
potential confounding | 3 |
search tool | 3 |
cases among | 3 |
paediatric ed | 3 |
viet nam | 3 |
increased detection | 3 |
negative samples | 3 |
bocavirus species | 3 |
weather parameter | 3 |
individual viruses | 3 |
cell receptor | 3 |
capsid gene | 3 |
seng hospital | 3 |
important causes | 3 |
home visits | 3 |
within families | 3 |
data suggest | 3 |
health study | 3 |
study used | 3 |
iu day | 3 |
using rt | 3 |
older individuals | 3 |
challenge studies | 3 |
water service | 3 |
risk associated | 3 |
cardiac death | 3 |
primers used | 3 |
census tracts | 3 |
whose samples | 3 |
much higher | 3 |
cytopathic effect | 3 |
varied according | 3 |
general practices | 3 |
inadvertently infected | 3 |
parameters considered | 3 |
overall protective | 3 |
case detectors | 3 |
among hcov | 3 |
virus disease | 3 |
virus bronchiolitis | 3 |
two swabs | 3 |
two reviewers | 3 |
clinical findings | 3 |
recent years | 3 |
lymphocyte ratio | 3 |
results suggest | 3 |
four laboratory | 3 |
defined ari | 3 |
rsv peaked | 3 |
collected citations | 3 |
work activity | 3 |
household income | 3 |
targeted vaccination | 3 |
tests taken | 3 |
different hrv | 3 |
cardiovascular effects | 3 |
west indies | 3 |
skin lesions | 3 |
abdominal pain | 3 |
commonly used | 3 |
neutered male | 3 |
acute viral | 3 |
care settings | 3 |
effects model | 3 |
new prescriptions | 3 |
ear fl | 3 |
influenza infections | 3 |
six years | 3 |
central role | 3 |
incidence rate | 3 |
study cohort | 3 |
general community | 3 |
prototype strains | 3 |
sensitive molecular | 3 |
national hospital | 3 |
lower proportion | 3 |
confounding factors | 3 |
causal relationship | 3 |
study respiratory | 3 |
hcovs detected | 3 |
human parvovirus | 3 |
ari pathogens | 3 |
sinus pain | 3 |
report sick | 3 |
among subjects | 3 |
information will | 3 |
volunteer challenge | 3 |
blood cell | 3 |
typhi salmonella | 3 |
viral clearance | 3 |
cause severe | 3 |
adult population | 3 |
ari patient | 3 |
vascular permeability | 3 |
experimental studies | 3 |
medical history | 3 |
health system | 3 |
across databases | 3 |
hiv prevalence | 3 |
metapneumovirus infections | 3 |
reported outbreak | 3 |
either hrv | 3 |
phase relationship | 3 |
respiratory picornaviruses | 3 |
case finding | 3 |
study demonstrates | 3 |
hospitalized adults | 3 |
younger age | 3 |
renal stones | 3 |
one mutant | 3 |
rural health | 3 |
infants admitted | 3 |
respiratory adenoviruses | 3 |
specimen quality | 3 |
va health | 3 |
genome sequences | 3 |
data found | 3 |
clinical spectrum | 3 |
financial support | 3 |
experienced higher | 3 |
broad ari | 3 |
health burden | 3 |
infection using | 3 |
pathogenic role | 3 |
united kingdom | 3 |
infectious virus | 3 |
remaining two | 3 |
laboratory results | 3 |
beneficial effect | 3 |
exploratory analysis | 3 |
eligibility criteria | 3 |
serious respiratory | 3 |
hospitalized cases | 3 |
extension step | 3 |
case detection | 3 |
socioeconomic inequalities | 3 |
smooth muscle | 3 |
detection compared | 3 |
influenza vaccines | 3 |
protein synthesis | 3 |
primary analysis | 3 |
classified within | 3 |
found hmpv | 3 |
evolutionary genetics | 3 |
care seeking | 3 |
study staff | 3 |
staff sickness | 3 |
small areas | 3 |
hrv capsid | 3 |
lower airways | 3 |
influenza negative | 3 |
rhinovirus illnesses | 3 |
two viruses | 3 |
sickness surveillance | 3 |
ill children | 3 |
study reported | 3 |
many viruses | 3 |
nasopharyngeal swab | 3 |
prospectively recruited | 3 |
processes will | 3 |
mortality associated | 3 |
symptoms reported | 3 |
seeplex rv | 3 |
heterotypic responses | 3 |
paediatric patients | 3 |
care facility | 3 |
bacterial etiology | 3 |
organic acids | 3 |
trials unit | 3 |
isolate hadv | 3 |
continuous variables | 3 |
neutrophil count | 3 |
analysis restricted | 3 |
colleagues detected | 3 |
fold increase | 3 |
citation index | 3 |
case ascertainment | 3 |
qt interval | 3 |
nasopharyngeal washes | 3 |
past days | 3 |
etiological agents | 3 |
will likely | 3 |
will use | 3 |
stem cell | 3 |
low prevalence | 3 |
insurance type | 3 |
airway infl | 3 |
terms searched | 3 |
hoa province | 3 |
colleagues reported | 3 |
fi vefold | 3 |
unscheduled health | 3 |
outbreak detection | 3 |
participant type | 3 |
one infection | 3 |
cab direct | 3 |
poverty census | 3 |
pcr product | 3 |
receptor interactions | 3 |
new rhinovirus | 3 |
disease study | 3 |
innate response | 3 |
trial high | 3 |
shaanxi province | 3 |
nasal exudate | 3 |
peoples living | 3 |
child characteristics | 3 |
months vs | 3 |
secondary comparison | 3 |
military recruits | 3 |
i interferon | 3 |
among asthmatic | 3 |
observed seasonality | 3 |
influenza respiratory | 3 |
thermo fisher | 3 |
one hcov | 3 |
impact diaries | 3 |
transplant recipients | 3 |
lrt disease | 3 |
analysis respiratory | 3 |
multicenter study | 3 |
universal fcv | 3 |
definitions used | 3 |
material deprivation | 3 |
cold wars | 3 |
american indian | 3 |
surveillance population | 3 |
prospero database | 3 |
patients may | 3 |
search string | 3 |
nagasaki university | 3 |
host immune | 3 |
absenteeism surveillance | 3 |
antiviral state | 3 |
source population | 3 |
influenza patients | 3 |
airway disease | 3 |
paediatric acute | 3 |
college station | 3 |
high incidence | 3 |
two cats | 3 |
english articles | 3 |
versus rsv | 3 |
decision support | 3 |
like illnesses | 3 |
ampicillin plus | 3 |
fairly similar | 3 |
rectal temperatures | 3 |
step rt | 3 |
may help | 3 |
bias assessment | 3 |
detecting influenza | 3 |
laboratory diagnosis | 3 |
community study | 3 |
prevent respiratory | 3 |
outpatient settings | 3 |
fi fth | 3 |
acute sinusitis | 3 |
ari viruses | 3 |
randomized clinical | 3 |
pediatric acute | 3 |
causing respiratory | 3 |
airway pressure | 3 |
cold season | 3 |
rhinovirus bronchiolitis | 3 |
expiratory wheezing | 3 |
strains isolated | 3 |
hrv isolates | 3 |
bacterial respiratory | 3 |
three cats | 3 |
greater risk | 3 |
data analysis | 3 |
dose frequency | 3 |
viral agent | 3 |
study also | 3 |
notifiable diseases | 3 |
rainy season | 3 |
clinical scoring | 3 |
expensive single | 3 |
data available | 3 |
using culture | 3 |
sequence data | 3 |
interpandemic influenza | 3 |
one half | 3 |
patient samples | 3 |
nm rm | 3 |
antiviral immunity | 3 |
associated respiratory | 3 |
single sample | 3 |
clinical presentations | 3 |
identifying respiratory | 3 |
bacterial co | 3 |
especially among | 3 |
virus activity | 3 |
rhinovirus serotype | 3 |
one participant | 3 |
airway obstruction | 3 |
preschool children | 3 |
bronchiolitis obliterans | 3 |
community survey | 3 |
live attenuated | 3 |
ki polyomaviruses | 3 |
viral tests | 3 |
respiratory signs | 3 |
compared effects | 3 |
hbov detection | 3 |
qtc lowering | 3 |
veterinary services | 3 |
manual review | 3 |
specimens may | 3 |
prior antibiotic | 3 |
children diagnosed | 3 |
postsecondary institutional | 3 |
hcov infection | 3 |
electron microscopy | 3 |
active hbov | 3 |
chinese databases | 3 |
detect small | 3 |
principal findings | 3 |
common bacteria | 3 |
key cost | 3 |
blood tests | 3 |
hrv positive | 3 |
antipsychotic drugs | 3 |
viral epidemiology | 3 |
likely due | 3 |
improved detection | 3 |
vaccine efficacy | 3 |
ethnic minorities | 3 |
placebo arms | 3 |
nonenveloped icosahedral | 3 |
heterogeneity will | 3 |
genus enterovirus | 3 |
diary returned | 3 |
tissue cultures | 3 |
age years | 3 |
hrv cases | 3 |
socioeconomic disparities | 3 |
data streams | 3 |
final extension | 3 |
like fever | 3 |
symptom diary | 3 |
frequent cause | 3 |
may play | 3 |
households living | 3 |
invitrogen carlsbad | 3 |
identified hadv | 3 |
sequence identity | 3 |
risk ratios | 3 |
studies identified | 3 |
group analyses | 3 |
differential susceptibility | 3 |
two national | 3 |
tract viruses | 3 |
daily symptom | 3 |
governmental report | 3 |
subjects experienced | 3 |
per year | 3 |
muscle aches | 3 |
nan doi | 3 |
greater proportion | 3 |
hbov positive | 3 |
severe cap | 3 |
general population | 3 |
still febrile | 3 |
yamagata lineage | 3 |
proportional odds | 3 |
breaths per | 3 |
airway viruses | 3 |
dual viral | 3 |
industrial population | 3 |
also thank | 3 |
substantial morbidity | 3 |
lung aspirates | 3 |
tropics viral | 3 |
may lead | 3 |
congenital heart | 3 |
one year | 3 |
viruses implicated | 3 |
significant bands | 3 |
increasingly recognized | 3 |
symptoms observed | 3 |
relatively high | 3 |
chief complaints | 3 |
findings suggest | 3 |
tertiary paediatric | 3 |
following variables | 3 |
defining clinically | 3 |
adenovirus infections | 3 |
discharge summaries | 3 |
slightly older | 3 |
virus human | 3 |
last days | 3 |
midturbinate swabs | 3 |
disease incidence | 3 |
may improve | 3 |
children viral | 3 |
complete nucleotide | 3 |
first author | 3 |
malaria season | 3 |
data support | 3 |
staphylococcus aureus | 3 |
experimentally infected | 3 |
epidemiologic characteristics | 3 |
clinical parameters | 3 |
disease pathogen | 3 |
biopsy specimen | 3 |
children date | 3 |
vaccination among | 3 |
studies examining | 3 |
rhinovirus strains | 3 |
higher frequencies | 3 |
weight gain | 3 |
independently associated | 3 |
hand washing | 3 |
quantitative real | 3 |
nasal wash | 3 |
regression analyses | 3 |
universal pcr | 3 |
study provides | 3 |
icu admission | 3 |
acute care | 3 |
deaths among | 3 |
chest indrawing | 3 |
versus single | 3 |
international classification | 3 |
wide variety | 3 |
outbreak management | 3 |
often used | 3 |
molecular epidemiology | 3 |
national reference | 3 |
maternal race | 3 |
influenza immunization | 3 |
population living | 3 |
online version | 3 |
using natural | 3 |
text classifier | 3 |
antiviral responses | 3 |
time frame | 3 |
experimental infection | 3 |
current illness | 3 |
total costs | 3 |
articles will | 3 |
quality control | 3 |
assays using | 3 |
ari season | 3 |
demographic characteristics | 3 |
causative pathogen | 3 |
gene sequences | 3 |
groups defined | 3 |
reviewers answer | 3 |
middle eastern | 3 |
helmholtz centre | 3 |
molecular screening | 3 |
participants reported | 3 |
without previous | 3 |
seeking health | 3 |
hrv epidemiology | 3 |
standard curve | 3 |
sickness absenteeism | 3 |
care home | 3 |
commercially available | 3 |
also used | 3 |
antibody response | 3 |
fi lters | 3 |
children enrolled | 2 |
among african | 2 |
wu polyomaviruses | 2 |
trials showing | 2 |
rhinovirus replication | 2 |
gross necropsy | 2 |
epidermal necrosis | 2 |
late summer | 2 |
agents associated | 2 |
yet defi | 2 |
adenoviral infections | 2 |
african countries | 2 |
allocated ampicillin | 2 |
includes hcov | 2 |
induced modulation | 2 |
epidemiological modeling | 2 |
studies collected | 2 |
benefits schedule | 2 |
felt comfortable | 2 |
clinical records | 2 |
ms change | 2 |
first dose | 2 |
often neglected | 2 |
identified amongst | 2 |
successful ari | 2 |
also affected | 2 |
particularly associated | 2 |
drug label | 2 |
specimens using | 2 |
antigen detection | 2 |
results available | 2 |
red blood | 2 |
respiratory hbov | 2 |
possible causal | 2 |
multivariable meta | 2 |
transcription factors | 2 |
urban children | 2 |
childhood infections | 2 |
cost drivers | 2 |
procaine penicillin | 2 |
disease human | 2 |
care hospitals | 2 |
two time | 2 |
technical assistance | 2 |
assessing risk | 2 |
better care | 2 |
last years | 2 |
retaining sensitivities | 2 |
corsican sentinelles | 2 |
participants received | 2 |
corresponding author | 2 |
special characters | 2 |
almost identical | 2 |
vitro hrv | 2 |
cell transplant | 2 |
care costs | 2 |
global summary | 2 |
assays may | 2 |
routine use | 2 |
detected simultaneously | 2 |
specific incidence | 2 |
demonstrated several | 2 |
study patients | 2 |
traditional methods | 2 |
disease virus | 2 |
persons hospitalized | 2 |
highly accepted | 2 |
contributed significantly | 2 |
weight three | 2 |
lower income | 2 |
children population | 2 |
previously healthy | 2 |
limited value | 2 |
chief complaint | 2 |
lymph nodes | 2 |
key roles | 2 |
respiratory initiative | 2 |
nucleotide identity | 2 |
va maryland | 2 |
quantitative multiplex | 2 |
summary impact | 2 |
collected nasopharyngeal | 2 |
fi ndings | 2 |
new species | 2 |
redmond wa | 2 |
tropical regions | 2 |
genus alphacoronavirus | 2 |
virus circulation | 2 |
concurrent respiratory | 2 |
higher hospitalization | 2 |
hospitalizations associated | 2 |
hcov strain | 2 |
population based | 2 |
longitudinal study | 2 |
asthma hospitalizations | 2 |
frequently identified | 2 |
study group | 2 |
additional cases | 2 |
viruses including | 2 |
reporting aris | 2 |
representative surveillance | 2 |
individual respiratory | 2 |
average virus | 2 |
times daily | 2 |
van nguyen | 2 |
human volunteers | 2 |
including fever | 2 |
study responding | 2 |
somewhat less | 2 |
distinct disease | 2 |
children rhinovirus | 2 |
routine patient | 2 |
relevant articles | 2 |
atopic people | 2 |
viruses identified | 2 |
significant rsv | 2 |
identity thresholds | 2 |
lrti group | 2 |
primary sinus | 2 |
crude flu | 2 |
data capture | 2 |
may prove | 2 |
temperate climates | 2 |
made clear | 2 |
interest relevant | 2 |
gastrointestinal infections | 2 |
allergy clin | 2 |
retrospective cohort | 2 |
aris caused | 2 |
detections occur | 2 |
reported social | 2 |
hay fever | 2 |
non flu | 2 |
classification algorithms | 2 |
linear regression | 2 |
environmental factors | 2 |
cause seasonal | 2 |
hrv among | 2 |
like rsv | 2 |
either alone | 2 |
moraxella catarrhalis | 2 |
rsv cases | 2 |
tropical medicine | 2 |
cutaneous edema | 2 |
coronavirus associated | 2 |
analysis using | 2 |
prescribe antibiotic | 2 |
pulmonary syndrome | 2 |
placebo controlled | 2 |
new viruses | 2 |
yellowish edema | 2 |
signaling pathways | 2 |
volunteer infection | 2 |
type iii | 2 |
asthmatic adult | 2 |
entry human | 2 |
showed significant | 2 |
geographic location | 2 |
containing hcov | 2 |
grouped together | 2 |
participants collect | 2 |
infections global | 2 |
genus bocavirus | 2 |
inverse association | 2 |
health inequalities | 2 |
rrna sequence | 2 |
overall incidence | 2 |
condition continued | 2 |
small airways | 2 |
polymorphisms may | 2 |
infancy predict | 2 |
surveillance case | 2 |
hematopoietic stem | 2 |
pcr clinical | 2 |
flow chart | 2 |
indigenous health | 2 |
hmpv infections | 2 |
absences due | 2 |
room air | 2 |
assay detection | 2 |
abstract review | 2 |
detect acute | 2 |
wage rates | 2 |
disease outbreak | 2 |
poorer discriminatory | 2 |
electronic laboratory | 2 |
mass screening | 2 |
np gene | 2 |
cytokine response | 2 |
outdoor cat | 2 |
cluster surveillance | 2 |
another hrv | 2 |
mycoplasma pneumonia | 2 |
treatment groups | 2 |
study populations | 2 |
new ari | 2 |
chronic shedding | 2 |
nonasthmatic siblings | 2 |
early event | 2 |
world emr | 2 |
generally associated | 2 |
rsv detection | 2 |
health outcome | 2 |
high rates | 2 |
crude non | 2 |
hospitalized pneumonia | 2 |
ecological study | 2 |
qiaamp minelute | 2 |
lung lobes | 2 |
peak temperature | 2 |
bacterial growth | 2 |
virus positivity | 2 |
control measures | 2 |
cholecalciferol supplementation | 2 |
severe aris | 2 |
symptoms related | 2 |
clin immunol | 2 |
viral disease | 2 |
virus panel | 2 |
wupyv exposure | 2 |
dollar values | 2 |
canadian provinces | 2 |
investigate rob | 2 |
working towards | 2 |
infectious hrv | 2 |
citations will | 2 |
using qiaamp | 2 |
study samples | 2 |
rhinorrhea compared | 2 |
exacerbations among | 2 |
four common | 2 |
remained anorectic | 2 |
adjusted life | 2 |
adult volunteer | 2 |
taken together | 2 |
low numbers | 2 |
ag ms | 2 |
several respiratory | 2 |
rwf bly | 2 |
detect influenza | 2 |
among school | 2 |
rmed hrv | 2 |
subsequent childhood | 2 |
third human | 2 |
pediatric practice | 2 |
highly sensitive | 2 |
one illness | 2 |
will expand | 2 |
sample processing | 2 |
weather effects | 2 |
whole study | 2 |
common circulating | 2 |
refi ned | 2 |
acute rhinovirus | 2 |
monitoring period | 2 |
information related | 2 |
perceived stress | 2 |
health conditions | 2 |
mean qtc | 2 |
previous rt | 2 |
strongly suggests | 2 |
literature search | 2 |
detect additional | 2 |
nontyphoidal salmonella | 2 |
multiple comparisons | 2 |
type allele | 2 |
health professionals | 2 |
common etiology | 2 |
another included | 2 |
questions related | 2 |
virological studies | 2 |
organ class | 2 |
ml transport | 2 |
cause symptoms | 2 |
disease risk | 2 |
neutralizes hrv | 2 |
program implemented | 2 |
pcr system | 2 |
may pose | 2 |
managed illness | 2 |
per week | 2 |
previously analyzed | 2 |
copy number | 2 |
without evidence | 2 |
automatically identify | 2 |
pooled odds | 2 |
extraction form | 2 |
rhinovirus human | 2 |
respiratory health | 2 |
one single | 2 |
inpatient settings | 2 |
virus neutralization | 2 |
australian preschool | 2 |
radiology reports | 2 |
hospitalization incidence | 2 |
eight studies | 2 |
virus culture | 2 |
normal immune | 2 |
premature birth | 2 |
identify key | 2 |
control region | 2 |
genetic sequence | 2 |